<DOC>
	<DOCNO>NCT02680561</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetic profile fluticasone propionate and/or salmeterol deliver single oral inhalation dose Fp MDPI FS MDPI .</brief_summary>
	<brief_title>A Double Blind Open Label Comparator Study Compare Treatments 4 11 Year Old Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>The patient male female age 4 11 year age , inclusive Severity disease : The patient persistent asthma Asthma diagnosis : The patient diagnosis asthma define NIH . The patient require less 4 inhalation per week rescue bronchodilator ( average ) 4 week precede SV . The patient able withhold ( judged investigator ) rescue medication least 6 hour SV treatment visit . The patient must weight 18 kg high . Additional criterion apply , please contact investigator information . The patient history lifethreatening asthma exacerbation define protocol asthma episode require intubation and/or associate hypercapnia , respiratory arrest , hypoxic seizure . Female patient reach puberty child bear potential must negative serum pregnancy test SV . Eligible menstruate female patient unwilling employ appropriate birth control measure ensure pregnancy exclude The patient participate randomized patient investigational drug study within 30 day ( start final followup visit study ) precede SV plan participate another investigational drug study time study . The patient know hypersensitivity corticosteroid , salmeterol , excipients study drug ( ie , lactose ) . The patient culturedocumented suspected bacterial viral upper respiratory tract infection ( URTI ) low respiratory tract infection ( LRTI ) , sinus , middle ear resolve least 2 week SV . The patient asthma exacerbation require systemic corticosteroid within 30 day SV , hospitalization asthma within 2 month SV . The patient use immunosuppressive medication within 4 week SV . The patient untreated oral candidiasis SV . Patients clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study . Note : Azole antifungal prohibit . The patient immediate relative employee investigational center . Patients donate whole blood 60 day first dose , receive donate plasma , white blood cell , platelet within 14 day first dose study drug , 90 day last dose study drug . The patient disease/condition medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . Additional criterion apply , please contact investigator information .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>